Zhong Guo Ji Jin Bao·2025-11-30 15:06Core Insights - Private equity firms have conducted over 44,000 research activities on A-share listed companies in 2023, with a focus on hard technology sectors such as electronics, biomedicine, and machinery [1][2] - The most researched industries include electronics, biomedicine, and machinery, with significant interest in artificial intelligence, innovative pharmaceuticals, and new consumption trends [1][4] Group 1: Research Activities - A total of 2,579 private equity firms participated in A-share research, covering 2,184 stocks across 30 primary industries, resulting in 44,702 research instances [2] - The electronics sector was the most researched, with 8,732 instances, followed by biomedicine with 6,341 and machinery with 5,437 [2][4] - Notable companies in the electronics sector include Luxshare Precision, which was researched 335 times, and other leading firms in biomedicine such as United Imaging Healthcare and Mindray Medical [2][3] Group 2: Private Equity Firm Activities - The most active private equity firm, Zhengyuan Investment, conducted 1,002 research activities, while other major firms like Panjing Investment and Gao Yi Asset also showed high engagement [2][3] - Panjing Investment focused on nearly 30 stocks with multiple research instances, including Luxshare Precision and Jiangbolong [3] - Gao Yi Asset showed a preference for biomedicine, electronics, and machinery, conducting six research activities on Zhongkong Technology [3] Group 3: Market Trends and Insights - The electronics industry is thriving due to accelerated domestic semiconductor replacement and the initiation of a consumer electronics innovation cycle [4] - The biomedicine sector is favored for its diverse stock options and the rapid approval of innovative drugs, alongside a recovery in medical consumption [4] - The power equipment sector benefits from the continuous growth of new energy installations, attracting significant research interest from private equity firms [4] Group 4: Future Outlook - The market is expected to shift from valuation-driven to performance-driven, with a focus on high-growth sectors such as artificial intelligence, innovative pharmaceuticals, and machinery [5][6] - Investment strategies will emphasize structural growth potential in emerging sectors and cyclical opportunities arising from "anti-involution" policies [6]